

Denver Health antibiotic stewardship application home screen



Topic

- Urinary tract infections (UTI) →
- Respiratory tract infections →
- Skin and soft tissue infections →
- Gastrointestinal infections →
- Ear, nose, and throat (ENT) →
- Sepsis →
- Genital tract infections →
- Musculoskeletal infections →
- Febrile neutropenia →
- Central nervous system infections (CNS) →
- Other infections →
- Perioperative antibiotic prophylaxis →
- Antimicrobial dose adjustments →
- Blood culture PCR interpretation →
- Antibiogram 2018 →

Example of institution-specific prescribing guidance for patients hospitalized with acute pyelonephritis

Inpatient management

Initial treatment, low risk of MDRO

Ceftriaxone 1 g IV Q24H

Mild PCN allergy:

No change

Moderate/severe PCN allergy:

Levofloxacin 750 mg IV/PO daily

Risk factors for multidrug resistant organisms (MDRO)

1. Previous infection or colonization with *P. aeruginosa* or extended-spectrum beta-lactamase (ESBL) *E. coli*
2. Residence at a nursing facility
3. Chronic indwelling urinary catheter

Initial treatment, higher risk of MDRO or severe sepsis

Cefepime 2 g IV Q12H

Mild PCN allergy:

No change

Moderate/severe PCN allergy:

Amikacin 15 mg/kg IV Q24H OR aztreonam 2 g IV Q8H

Oral step-down therapy

If isolate susceptible, narrow antibiotic (listed preferred to least preferred):

1. TMP/SMX DS 1 tab PO BID to complete 10 total days of therapy
2. Cefdinir 300 mg PO BID to complete 10 total days of therapy
3. Levofloxacin 750 mg PO daily to complete 5 total days of therapy